U.S. Medical Glove Company (USMGC), the only American manufacturer of the machinery, chemicals, and materials required to produce both nitrile and polyisoprene gloves,  announced the execution of a master lease for a 638,000 square-foot manufacturing facility in Ohio, managed by CAI Investments LLC.

This critical move marks the final phase in USMGC's mission to build and secure a 100% American-made medical and surgical glove supply chain—free from reliance on China or any foreign supplier.

At a time when global instability and unfair trade practices continue to threaten the availability of essential healthcare products, USMGC is leading the charge to restore American manufacturing leadership. With this new facility, the United States will have the sovereign capacity to produce its own gloves, on its own soil, using its own machines, raw materials, and workforce.

The facility will place a significant emphasis on the manufacturing of USA-made NBR (nitrile butadiene rubber), the critical raw material used in nitrile glove production, but it will also be a hub to produce surgical and specialty gloves.

This acquisition complements USMGC's existing operations in Honea Path, South Carolina, where it produces polyisoprene, the essential raw material used in surgical glove manufacturing. Together, the South Carolina and Ohio facilities allow USMGC to fully control and domestically produce the raw materials required for both nitrile medical exam gloves and polyisoprene surgical gloves, completing an end-to-end American supply chain for the nation's critical glove needs.

In addition to producing its own NBR on-site—ensuring greater supply chain control and cost e?ciency (saving approximately USD 20 million per year in shipping costs from Asia alone)—the facility will also house 18 state-of-the-art surgical and specialty glove production machines. These lines are expected to increase revenue and profit margins, as well as total glove production capacity.

While the primary focus will be on surgical glove manufacturing, the facility will also produce nitrile medical exam gloves and a diverse range of specialty gloves to meet the demands of both healthcare and industrial sectors.

"With this acquisition, USMGC now controls every step of surgical glove production—from raw materials to finished gloves—right here in America," says Lucas Muriello, CFO of USMGC. "That means faster turnaround times and greater quality assurance, as well as a safer, more secure and dependable future for America's frontline workers. It also means an end to the reliance on China and other foreign suppliers."

The facility, which includes 15 railcar spots, 25 MW of power capacity, and a valid Air Quality Permit from the Ohio Environmental Protection Agency, will undergo a multi-phase transformation with an estimated USD 200 to USD 240 million investment.